We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Proton Therapy Has Better Outcome over IMRT for Advanced Head and Neck Cancers

By MedImaging International staff writers
Posted on 22 Jul 2014
Radiation oncologists compared the world’s literature on outcomes of proton beam therapy in the treatment of a range of advanced head and neck cancers of the skull base compared to intensity-modulated radiation therapy (IMRT) and found that proton beam therapy significantly improved disease-free survival and tumor control when compared to IMRT.

The study’s findings were published June 27, 2014, in the journal Lancet Oncology. “We undertook a systematic review and meta-analysis to compare the clinical outcomes of patients treated with proton therapy with patients receiving photon IMRT,” said senior author Robert Foote, MD, a radiation oncologist at the Mayo Clinic (Rochester, MN, USA). “Our findings suggest that the theoretical advantages of proton beam therapy may in fact be real.”

Researchers reviewed cases of nasal cavity and paranasal sinus tumors through extensive database searches. They included studies of patients who had no earlier treatment—neither primary radiation therapy nor adjuvant radiation therapy—and patients who had recurrent disease. Researchers collected data on overall survival, disease-free survival, and tumor control, at five years and at the patient’s longest follow-up. They used random-effect models to pool outcomes across studies and compared event rates of combined outcomes for proton therapy and IMRT using an interaction test.

Researchers discovered disease-free survival to be significantly higher at five years for patients receiving proton therapy than for patients receiving IMRT (72% versus 50%). Tumor control did not differ between treatment groups at five years however tumor control was higher for patients receiving proton therapy than for IMRT at the longest follow-up (81% versus 64%).


Related Links:

Mayo Clinic



Gold Member
Ultrasound System
FUTUS LE
Gold Member
Electrode Solution and Skin Prep
Signaspray
Mobile Radiographic System
XJET
Portable DR Flat Panel Detector
VIVIX-S 1012N

Latest Nuclear Medicine News

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors
21 Jul 2014  |   Nuclear Medicine

Novel PET Imaging Approach Offers Never-Before-Seen View of Neuroinflammation
21 Jul 2014  |   Nuclear Medicine

Novel Radiotracer Identifies Biomarker for Triple-Negative Breast Cancer
21 Jul 2014  |   Nuclear Medicine